ProCE Banner Activity

Considerations in Selecting Therapy for Previously Treated CLL

Slideset Download
Download these slides from our ASH 2019 live satellite symposium on CLL to review the most current clinical data on treating patients with relapsed/refractory CLL.

Released: December 05, 2019

Expiration: December 03, 2020

No longer available for credit.

Share

Faculty

Asher Chanan-Khan

Asher Chanan-Khan, MD

Associate Professor of Oncology
Attending Physician
, Department of Medicine
Member, Department of Pharmacology and Therapeutics
Roswell Park Cancer Institute
Buffalo, New York

Provided by

Provided by National Comprehensive Cancer Network.
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

BeiGene, Ltd.

Janssen Biotech Pharmacyclics

Pharmacyclics an AbbVie Company

Faculty Disclosure

Primary Author

Asher Chanan-Khan, MD

Associate Professor of Oncology
Attending Physician
, Department of Medicine
Member, Department of Pharmacology and Therapeutics
Roswell Park Cancer Institute
Buffalo, New York

Asher Chanan-Khan, MD, has no relevant conflicts of interest to report.